| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy | 77 | 2021 | 994 | 4.120 |
Why?
|
| Pregnancy Complications | 17 | 2018 | 105 | 3.580 |
Why?
|
| Postpartum Hemorrhage | 13 | 2020 | 18 | 2.350 |
Why?
|
| Oxytocics | 6 | 2017 | 13 | 2.330 |
Why?
|
| Labor, Induced | 9 | 2018 | 17 | 2.300 |
Why?
|
| Cesarean Section | 17 | 2020 | 112 | 2.230 |
Why?
|
| Oxytocin | 7 | 2017 | 27 | 1.980 |
Why?
|
| Receptors, Oxytocin | 4 | 2017 | 8 | 1.940 |
Why?
|
| Delivery, Obstetric | 13 | 2020 | 58 | 1.760 |
Why?
|
| Pregnancy Outcome | 14 | 2018 | 90 | 1.720 |
Why?
|
| Female | 89 | 2021 | 19859 | 1.680 |
Why?
|
| Uterine Contraction | 4 | 2016 | 7 | 1.560 |
Why?
|
| Adult | 56 | 2021 | 9327 | 1.550 |
Why?
|
| Uterus | 4 | 2016 | 93 | 1.480 |
Why?
|
| Pre-Eclampsia | 6 | 2020 | 66 | 1.460 |
Why?
|
| Obstetric Labor Complications | 5 | 2017 | 18 | 1.460 |
Why?
|
| Humans | 87 | 2021 | 31836 | 1.240 |
Why?
|
| Chorioamnionitis | 5 | 2018 | 10 | 1.230 |
Why?
|
| Magnesium Sulfate | 2 | 2018 | 14 | 1.190 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 2 | 2017 | 2 | 1.130 |
Why?
|
| Cerebral Palsy | 2 | 2018 | 62 | 1.130 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2018 | 24 | 1.130 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 70 | 1.100 |
Why?
|
| Gestational Age | 13 | 2020 | 120 | 1.010 |
Why?
|
| Labor, Obstetric | 5 | 2020 | 36 | 1.010 |
Why?
|
| Trial of Labor | 3 | 2020 | 19 | 1.000 |
Why?
|
| Adrenomedullin | 3 | 2014 | 4 | 0.980 |
Why?
|
| Premature Birth | 7 | 2021 | 66 | 0.960 |
Why?
|
| Young Adult | 21 | 2021 | 2603 | 0.870 |
Why?
|
| Logistic Models | 14 | 2018 | 777 | 0.870 |
Why?
|
| Fetal Membranes, Premature Rupture | 6 | 2019 | 13 | 0.870 |
Why?
|
| Trophoblasts | 2 | 2013 | 10 | 0.850 |
Why?
|
| Pyelonephritis | 4 | 2015 | 9 | 0.850 |
Why?
|
| Smoke | 2 | 2013 | 16 | 0.850 |
Why?
|
| Misoprostol | 2 | 2016 | 5 | 0.830 |
Why?
|
| Cervix Uteri | 3 | 2012 | 27 | 0.830 |
Why?
|
| Infant, Newborn | 11 | 2021 | 665 | 0.810 |
Why?
|
| Body Mass Index | 10 | 2018 | 916 | 0.800 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2014 | 42 | 0.800 |
Why?
|
| Pregnancy Trimester, Third | 4 | 2020 | 18 | 0.780 |
Why?
|
| Diabetes, Gestational | 2 | 2014 | 24 | 0.770 |
Why?
|
| Patient Participation | 1 | 2020 | 80 | 0.680 |
Why?
|
| Stillbirth | 2 | 2016 | 7 | 0.630 |
Why?
|
| Seat Belts | 2 | 2015 | 17 | 0.630 |
Why?
|
| Abortion, Spontaneous | 2 | 2010 | 12 | 0.630 |
Why?
|
| Obesity, Morbid | 5 | 2018 | 71 | 0.620 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2018 | 11 | 0.620 |
Why?
|
| Labor Presentation | 1 | 2018 | 1 | 0.620 |
Why?
|
| Progesterone | 2 | 2015 | 95 | 0.620 |
Why?
|
| Retinopathy of Prematurity | 1 | 2018 | 8 | 0.620 |
Why?
|
| Magnesium | 1 | 2018 | 30 | 0.610 |
Why?
|
| Infant Mortality | 1 | 2018 | 22 | 0.600 |
Why?
|
| Retrospective Studies | 17 | 2020 | 3488 | 0.600 |
Why?
|
| Fetal Blood | 1 | 2018 | 38 | 0.600 |
Why?
|
| Cytokines | 2 | 2016 | 259 | 0.600 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2015 | 32 | 0.600 |
Why?
|
| Cell Movement | 3 | 2013 | 170 | 0.600 |
Why?
|
| Decidua | 2 | 2016 | 18 | 0.600 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2017 | 40 | 0.590 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2018 | 27 | 0.590 |
Why?
|
| Pregnancy Trimester, First | 2 | 2014 | 9 | 0.580 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 28 | 0.580 |
Why?
|
| Tranexamic Acid | 1 | 2017 | 5 | 0.570 |
Why?
|
| Blood Coagulation | 1 | 2017 | 13 | 0.570 |
Why?
|
| Risk Factors | 17 | 2016 | 3851 | 0.570 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 16 | 0.570 |
Why?
|
| Thrombin | 1 | 2016 | 15 | 0.570 |
Why?
|
| Heparin | 1 | 2016 | 74 | 0.550 |
Why?
|
| Pregnant Women | 1 | 2015 | 6 | 0.530 |
Why?
|
| Myometrium | 2 | 2013 | 11 | 0.530 |
Why?
|
| Continental Population Groups | 2 | 2016 | 236 | 0.520 |
Why?
|
| Uterine Inertia | 2 | 2016 | 2 | 0.520 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 148 | 0.510 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 27 | 0.510 |
Why?
|
| Health Status Disparities | 1 | 2016 | 122 | 0.510 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 31 | 0.510 |
Why?
|
| Vitamin D | 1 | 2016 | 183 | 0.500 |
Why?
|
| Pregnancy in Diabetics | 1 | 2014 | 6 | 0.500 |
Why?
|
| Hospitalization | 2 | 2015 | 463 | 0.500 |
Why?
|
| Thrombophilia | 1 | 2014 | 7 | 0.500 |
Why?
|
| Rheumatic Diseases | 1 | 2014 | 7 | 0.500 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 686 | 0.480 |
Why?
|
| Maternal Age | 1 | 2014 | 15 | 0.480 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 23 | 0.470 |
Why?
|
| Cerclage, Cervical | 2 | 2012 | 6 | 0.470 |
Why?
|
| Muscle Contraction | 3 | 2020 | 113 | 0.460 |
Why?
|
| Ethnic Groups | 1 | 2016 | 476 | 0.450 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 55 | 0.450 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 239 | 0.430 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 1067 | 0.430 |
Why?
|
| Smoking | 2 | 2014 | 499 | 0.430 |
Why?
|
| Inflammation | 1 | 2016 | 540 | 0.430 |
Why?
|
| Prevalence | 5 | 2018 | 979 | 0.420 |
Why?
|
| Chorion | 5 | 2015 | 9 | 0.410 |
Why?
|
| United States | 8 | 2020 | 3925 | 0.410 |
Why?
|
| Obesity | 3 | 2017 | 1158 | 0.400 |
Why?
|
| Kidney Diseases | 1 | 2014 | 249 | 0.400 |
Why?
|
| Tobacco | 1 | 2012 | 57 | 0.390 |
Why?
|
| Uterine Hemorrhage | 1 | 2011 | 8 | 0.380 |
Why?
|
| Arrestins | 1 | 2010 | 3 | 0.380 |
Why?
|
| Labor Onset | 1 | 2010 | 1 | 0.380 |
Why?
|
| Blood Transfusion | 3 | 2020 | 73 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 629 | 0.370 |
Why?
|
| Vaginal Fistula | 1 | 2010 | 2 | 0.370 |
Why?
|
| Signal Transduction | 2 | 2013 | 687 | 0.370 |
Why?
|
| Fistula | 1 | 2010 | 11 | 0.360 |
Why?
|
| Hypertension | 2 | 2014 | 956 | 0.360 |
Why?
|
| Linear Models | 4 | 2014 | 449 | 0.340 |
Why?
|
| Case-Control Studies | 5 | 2017 | 895 | 0.340 |
Why?
|
| Prospective Studies | 5 | 2020 | 2277 | 0.330 |
Why?
|
| Adolescent | 9 | 2020 | 3511 | 0.320 |
Why?
|
| Hydatidiform Mole | 1 | 2008 | 4 | 0.320 |
Why?
|
| Time Factors | 6 | 2017 | 2146 | 0.310 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 26 | 0.310 |
Why?
|
| Uterine Rupture | 1 | 2008 | 18 | 0.310 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2008 | 17 | 0.310 |
Why?
|
| Postpartum Period | 3 | 2016 | 33 | 0.300 |
Why?
|
| Cohort Studies | 7 | 2020 | 1824 | 0.300 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 1122 | 0.280 |
Why?
|
| Birth Weight | 2 | 2018 | 47 | 0.270 |
Why?
|
| Alkalosis | 1 | 2006 | 2 | 0.270 |
Why?
|
| Pica | 1 | 2006 | 2 | 0.270 |
Why?
|
| Sodium Bicarbonate | 1 | 2006 | 6 | 0.270 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 6 | 0.270 |
Why?
|
| Hypokalemia | 1 | 2006 | 14 | 0.270 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2005 | 1 | 0.270 |
Why?
|
| Abortion, Incomplete | 1 | 2005 | 1 | 0.270 |
Why?
|
| Cells, Cultured | 4 | 2018 | 833 | 0.260 |
Why?
|
| Extraembryonic Membranes | 3 | 2014 | 4 | 0.260 |
Why?
|
| Hydroxyprogesterones | 2 | 2015 | 4 | 0.260 |
Why?
|
| Prenatal Diagnosis | 3 | 2018 | 24 | 0.260 |
Why?
|
| Blood Component Transfusion | 3 | 2016 | 10 | 0.260 |
Why?
|
| Perineum | 2 | 2020 | 18 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 766 | 0.250 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2004 | 13 | 0.240 |
Why?
|
| Varicose Veins | 2 | 2018 | 6 | 0.240 |
Why?
|
| Odds Ratio | 3 | 2015 | 470 | 0.240 |
Why?
|
| Ureteral Obstruction | 1 | 2004 | 28 | 0.240 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 30 | 0.240 |
Why?
|
| Progestins | 2 | 2015 | 20 | 0.240 |
Why?
|
| Suture Techniques | 1 | 2004 | 60 | 0.240 |
Why?
|
| Prenatal Care | 3 | 2017 | 51 | 0.230 |
Why?
|
| Hysterectomy | 2 | 2020 | 45 | 0.230 |
Why?
|
| Receptors, Progesterone | 2 | 2014 | 63 | 0.230 |
Why?
|
| Malignant Hyperthermia | 1 | 2003 | 4 | 0.220 |
Why?
|
| RNA, Messenger | 3 | 2015 | 508 | 0.220 |
Why?
|
| Cell Line | 3 | 2013 | 434 | 0.220 |
Why?
|
| Animals | 7 | 2020 | 7450 | 0.220 |
Why?
|
| Muscular Diseases | 1 | 2003 | 22 | 0.220 |
Why?
|
| Male | 9 | 2020 | 19091 | 0.220 |
Why?
|
| Gene Expression | 2 | 2016 | 334 | 0.210 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 57 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2014 | 257 | 0.200 |
Why?
|
| Accidents, Traffic | 2 | 2015 | 194 | 0.200 |
Why?
|
| Models, Statistical | 2 | 2020 | 173 | 0.190 |
Why?
|
| Steroids | 1 | 2021 | 38 | 0.190 |
Why?
|
| Expert Systems | 1 | 2020 | 4 | 0.180 |
Why?
|
| Birthing Centers | 1 | 2020 | 2 | 0.180 |
Why?
|
| Uterine Artery Embolization | 1 | 2020 | 4 | 0.180 |
Why?
|
| Computer Graphics | 1 | 2020 | 10 | 0.180 |
Why?
|
| Lacerations | 1 | 2020 | 9 | 0.180 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 493 | 0.180 |
Why?
|
| Amnion | 3 | 2015 | 37 | 0.180 |
Why?
|
| Wounds and Injuries | 2 | 2013 | 249 | 0.180 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 61 | 0.180 |
Why?
|
| Operating Rooms | 1 | 2020 | 33 | 0.180 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 75 | 0.170 |
Why?
|
| Double-Blind Method | 2 | 2020 | 523 | 0.170 |
Why?
|
| Tocolysis | 1 | 2019 | 1 | 0.170 |
Why?
|
| Tocolytic Agents | 1 | 2019 | 1 | 0.170 |
Why?
|
| Vaccination | 2 | 2017 | 136 | 0.170 |
Why?
|
| Obstetric Labor, Premature | 1 | 2019 | 10 | 0.170 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 247 | 0.170 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2019 | 26 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2018 | 25 | 0.160 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2018 | 3 | 0.160 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 128 | 0.160 |
Why?
|
| Treatment Outcome | 6 | 2015 | 3294 | 0.160 |
Why?
|
| Mice, Knockout | 2 | 2020 | 444 | 0.160 |
Why?
|
| Genotype | 3 | 2017 | 727 | 0.160 |
Why?
|
| Fetal Weight | 2 | 2018 | 6 | 0.160 |
Why?
|
| Respiration, Artificial | 2 | 2013 | 98 | 0.160 |
Why?
|
| Abdominal Wall | 1 | 2018 | 22 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2020 | 159 | 0.160 |
Why?
|
| Fetal Development | 1 | 2018 | 25 | 0.160 |
Why?
|
| African Americans | 2 | 2016 | 1428 | 0.160 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 81 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2020 | 1431 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 58 | 0.150 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 5 | 0.150 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2018 | 109 | 0.150 |
Why?
|
| Decision Making | 1 | 2020 | 194 | 0.150 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 24 | 0.150 |
Why?
|
| Rh-Hr Blood-Group System | 2 | 2008 | 5 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 231 | 0.150 |
Why?
|
| Hispanic Americans | 2 | 2016 | 942 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 2018 | 65 | 0.150 |
Why?
|
| Forecasting | 1 | 2018 | 144 | 0.150 |
Why?
|
| North Carolina | 6 | 2020 | 1514 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 874 | 0.150 |
Why?
|
| Data Collection | 1 | 2017 | 180 | 0.140 |
Why?
|
| False Positive Reactions | 2 | 2008 | 31 | 0.140 |
Why?
|
| Thrombelastography | 1 | 2017 | 2 | 0.140 |
Why?
|
| Muscle, Smooth | 1 | 2017 | 70 | 0.140 |
Why?
|
| Infant | 2 | 2018 | 1055 | 0.140 |
Why?
|
| Calcium Channels | 1 | 2017 | 57 | 0.140 |
Why?
|
| Mice | 4 | 2020 | 2476 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2021 | 293 | 0.130 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2015 | 3 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 61 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 513 | 0.130 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2015 | 19 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2010 | 378 | 0.130 |
Why?
|
| Hydroxylation | 1 | 2015 | 4 | 0.130 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2015 | 4 | 0.130 |
Why?
|
| Microsomes | 1 | 2015 | 13 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 40 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2016 | 189 | 0.130 |
Why?
|
| Workload | 1 | 2015 | 38 | 0.130 |
Why?
|
| Isoenzymes | 1 | 2015 | 61 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2015 | 70 | 0.130 |
Why?
|
| Pregnancy, Animal | 1 | 2015 | 19 | 0.130 |
Why?
|
| Telemetry | 1 | 2015 | 26 | 0.130 |
Why?
|
| Placenta | 1 | 2016 | 74 | 0.130 |
Why?
|
| Pregnancy, Multiple | 1 | 2015 | 10 | 0.130 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2015 | 93 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 85 | 0.120 |
Why?
|
| Protein Precursors | 1 | 2014 | 22 | 0.120 |
Why?
|
| Disease Management | 1 | 2015 | 126 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 94 | 0.120 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 2 | 2015 | 2 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 504 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1527 | 0.120 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2013 | 3 | 0.120 |
Why?
|
| Professional Practice | 1 | 2014 | 24 | 0.120 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2013 | 2 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2015 | 190 | 0.120 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2013 | 8 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 211 | 0.120 |
Why?
|
| Fibrinolysis | 1 | 2013 | 7 | 0.120 |
Why?
|
| Autistic Disorder | 1 | 2013 | 8 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 25 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2014 | 115 | 0.110 |
Why?
|
| Bacteria | 1 | 2014 | 46 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 127 | 0.110 |
Why?
|
| Anemia | 1 | 2013 | 59 | 0.110 |
Why?
|
| Hormone Antagonists | 1 | 2013 | 5 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 298 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 409 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2014 | 487 | 0.110 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2012 | 3 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2013 | 122 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 13 | 0.100 |
Why?
|
| Cervical Ripening | 1 | 2011 | 2 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 247 | 0.100 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1169 | 0.100 |
Why?
|
| Catheterization | 1 | 2011 | 58 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2015 | 306 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2014 | 491 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 110 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 1187 | 0.100 |
Why?
|
| Stimulation, Chemical | 1 | 2010 | 13 | 0.090 |
Why?
|
| Cell Survival | 1 | 2012 | 286 | 0.090 |
Why?
|
| Palpation | 1 | 2010 | 9 | 0.090 |
Why?
|
| Hematocrit | 1 | 2010 | 23 | 0.090 |
Why?
|
| Middle Aged | 5 | 2020 | 11824 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 37 | 0.090 |
Why?
|
| Pregnancy, High-Risk | 1 | 2010 | 2 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2010 | 91 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2011 | 251 | 0.090 |
Why?
|
| Rh Isoimmunization | 2 | 2008 | 2 | 0.090 |
Why?
|
| Transfection | 1 | 2010 | 191 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 114 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2010 | 292 | 0.090 |
Why?
|
| Nicotine | 1 | 2012 | 171 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 300 | 0.080 |
Why?
|
| Abortion, Therapeutic | 1 | 2008 | 1 | 0.080 |
Why?
|
| Suction | 1 | 2008 | 10 | 0.080 |
Why?
|
| Pregnancy, Ectopic | 1 | 2008 | 8 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2009 | 109 | 0.080 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 3 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 53 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2010 | 598 | 0.080 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 125 | 0.080 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Infant, Premature, Diseases | 2 | 2020 | 24 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 2271 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2007 | 34 | 0.070 |
Why?
|
| Oligomenorrhea | 1 | 2006 | 1 | 0.070 |
Why?
|
| Anovulation | 1 | 2006 | 5 | 0.070 |
Why?
|
| Anal Canal | 1 | 2006 | 20 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2006 | 25 | 0.070 |
Why?
|
| Dystocia | 1 | 2005 | 2 | 0.070 |
Why?
|
| Birth Injuries | 1 | 2005 | 28 | 0.060 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2005 | 36 | 0.060 |
Why?
|
| Pregnancy, Prolonged | 1 | 2004 | 1 | 0.060 |
Why?
|
| Hemostatic Techniques | 1 | 2004 | 7 | 0.060 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 23 | 0.060 |
Why?
|
| Uterine Diseases | 1 | 2004 | 20 | 0.060 |
Why?
|
| Endometrium | 1 | 2005 | 175 | 0.060 |
Why?
|
| Endometriosis | 1 | 2004 | 98 | 0.060 |
Why?
|
| Radiography | 1 | 2004 | 376 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 1498 | 0.050 |
Why?
|
| Fetal Macrosomia | 2 | 2014 | 5 | 0.050 |
Why?
|
| Perinatal Mortality | 1 | 2020 | 2 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2020 | 5 | 0.050 |
Why?
|
| Fetal Distress | 1 | 2020 | 3 | 0.050 |
Why?
|
| Morbidity | 1 | 2021 | 99 | 0.050 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2020 | 23 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 167 | 0.050 |
Why?
|
| Child | 2 | 2020 | 2425 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2020 | 37 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 51 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 589 | 0.040 |
Why?
|
| Obstetrics | 1 | 2020 | 26 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 72 | 0.040 |
Why?
|
| Clenbuterol | 1 | 2018 | 2 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2018 | 26 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2019 | 33 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 48 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 635 | 0.040 |
Why?
|
| Models, Econometric | 1 | 2018 | 8 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2018 | 38 | 0.040 |
Why?
|
| Polysomnography | 1 | 2018 | 40 | 0.040 |
Why?
|
| Growth Charts | 1 | 2018 | 4 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 73 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2018 | 159 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 185 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 247 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 899 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2016 | 12 | 0.040 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2015 | 10 | 0.030 |
Why?
|
| DNA | 2 | 2008 | 227 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2015 | 10 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 764 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 15 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2015 | 16 | 0.030 |
Why?
|
| Neuromuscular Diseases | 1 | 2015 | 14 | 0.030 |
Why?
|
| Pressure | 1 | 2015 | 51 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 2015 | 14 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 43 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 16 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 80 | 0.030 |
Why?
|
| Pneumonia | 1 | 2015 | 66 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 124 | 0.030 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2014 | 1 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 261 | 0.030 |
Why?
|
| Hemostatics | 1 | 2014 | 11 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2014 | 11 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2014 | 34 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 18 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2013 | 3 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 33 | 0.030 |
Why?
|
| Antithrombin III | 1 | 2013 | 4 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 40 | 0.030 |
Why?
|
| Hypothermia, Induced | 1 | 2013 | 17 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 17 | 0.030 |
Why?
|
| Birth Certificates | 1 | 2013 | 4 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2013 | 44 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2013 | 18 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 79 | 0.030 |
Why?
|
| Parity | 1 | 2013 | 20 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2013 | 68 | 0.030 |
Why?
|
| Abruptio Placentae | 1 | 2013 | 7 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2015 | 122 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 518 | 0.030 |
Why?
|
| Fetal Death | 1 | 2013 | 9 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 135 | 0.030 |
Why?
|
| Air Bags | 1 | 2013 | 15 | 0.030 |
Why?
|
| Schools | 1 | 2013 | 65 | 0.030 |
Why?
|
| Motor Vehicles | 1 | 2013 | 25 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 291 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 76 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 318 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2015 | 325 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 531 | 0.030 |
Why?
|
| Ampicillin | 1 | 2011 | 3 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 564 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2013 | 537 | 0.030 |
Why?
|
| Emergencies | 1 | 2012 | 47 | 0.030 |
Why?
|
| Azithromycin | 1 | 2011 | 14 | 0.030 |
Why?
|
| Sex Factors | 1 | 2013 | 662 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 295 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 162 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 515 | 0.020 |
Why?
|
| Mothers | 1 | 2011 | 88 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 404 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1259 | 0.020 |
Why?
|
| New Jersey | 1 | 2009 | 9 | 0.020 |
Why?
|
| Apgar Score | 1 | 2009 | 8 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2009 | 32 | 0.020 |
Why?
|
| Oocyte Retrieval | 1 | 2008 | 2 | 0.020 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2008 | 4 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2008 | 13 | 0.020 |
Why?
|
| Live Birth | 1 | 2008 | 7 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2008 | 19 | 0.020 |
Why?
|
| Embryo Transfer | 1 | 2008 | 10 | 0.020 |
Why?
|
| Fertilization in Vitro | 1 | 2008 | 22 | 0.020 |
Why?
|
| Balloon Occlusion | 1 | 2008 | 36 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 124 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1192 | 0.020 |
Why?
|
| Pregnancy Trimesters | 1 | 2006 | 3 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 262 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 44 | 0.020 |
Why?
|
| Health Surveys | 1 | 2006 | 196 | 0.020 |
Why?
|
| Episiotomy | 1 | 2005 | 2 | 0.020 |
Why?
|
| Obstetrical Forceps | 1 | 2005 | 3 | 0.020 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2005 | 4 | 0.020 |
Why?
|
| Maryland | 1 | 2005 | 28 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2005 | 22 | 0.020 |
Why?
|
| Weight Loss | 1 | 2006 | 465 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 1323 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 3988 | 0.010 |
Why?
|
| Aged | 1 | 2004 | 10288 | 0.010 |
Why?
|